However, extensive studies showed fairly low response rates: <5% regardless of which agent was used to target PD‐1/PD‐L1.[1] More recently, targeting immunometabolism as a potential mechanism for enhancing anti‐PD‐1 therapy was found to be effective against melanoma.[2] One such mechanism identified to treat melanoma was an immune‐metabolite Sphingosine‐1‐phosphate (S1P).[2]. The gene discussed is CD274; the disease is melanoma.